Form 13-F position report

PLUS THERAPEUTICS INC

Reported by Ashton Thomas Private Wealth LLC

PSTV CUSIP 72941H509 Manager CIK 0002019663

First reported at 815 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 815 Quarter-end amount reported
Reported value $1,198 Fair value at quarter end
Consecutive quarters held 1 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-06-30 6605
2022-09-30 5442
2022-12-31 3877
2023-03-31 3547
2023-06-30 0
2024-06-30 1198
2024-09-30 18853
2024-12-31 0
2025-12-31 12763
2026-03-31 5352
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for PLUS THERAPEUTICS INC held by Ashton Thomas Private Wealth LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -32,913 (-100.0%) 0 $0 2026-07-29
Q1 2026 Added 32,913 +8,000 (32.1%) < 0.01% $5,352 2026-05-11
Q4 2025 New 24,913 +24,913 (0.0%) < 0.01% $12,763 2026-01-29
Q4 2024 Reduced 0 -12,913 (-100.0%) 0 $0 2025-02-07
Q3 2024 Added 12,913 +12,098 (1484.4%) < 0.01% $18,853 2024-11-05
Q2 2024 New 815 +815 (0.0%) < 0.01% $1,198 2024-08-07
Q2 2023 Reduced 0 -12,230 (-100.0%) 0 $0 2024-04-23
Q1 2023 Unchanged 12,230 0 (0.0%) < 0.01% $3,547 2024-04-23
Q4 2022 Unchanged 12,230 0 (0.0%) < 0.01% $3,877 2024-04-22
Q3 2022 Unchanged 12,230 0 (0.0%) < 0.01% $5,442 2024-04-22
Q2 2022 New 12,230 +12,230 (0.0%) < 0.01% $6,605 2024-04-22

Who else reported the position

15 managers reported PLUS THERAPEUTICS INC for Q2 2024.

Managers reporting PLUS THERAPEUTICS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
AIGH Capital Management LLC New 568,681 +568,681 0.26% $835,961 1 qtr
GEODE CAPITAL MANAGEMENT LLC Added 46,648 +17,385 < 0.01% $68,572 5 qtrs
VANGUARD GROUP INC Unchanged 32,541 0 < 0.01% $47,835 5 qtrs
CITADEL ADVISORS LLC Added 18,283 +7,574 < 0.01% $26,876 3 qtrs
BlackRock Inc Unchanged 6,960 0 < 0.01% $10,231 5 qtrs
Tower Research Capital LLC TRC Added 4,186 +356 < 0.01% $6,153 5 qtrs
UBS Group AG New 3,199 +3,199 < 0.01% $4,703 4 qtrs
Ashton Thomas Private Wealth LLC This report New 815 +815 < 0.01% $1,198 1 qtr
ADVISOR GROUP HOLDINGS INC Unchanged 133 0 < 0.01% $195 5 qtrs
JPMorgan Chase & Co Unchanged 100 0 < 0.01% $147 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 07, 2024
Filing type
13F-HR
Position type
Stock

Voting authority reported

Sole
815
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.